Navigation Links
AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
Date:3/11/2009

ar.

Moving forward, we will continue to concentrate our efforts on bringing cetrorelix closer to market in collaboration with our partner, sanofi-aventis. We believe that this compound could prove to be a novel treatment for the benefit of millions of men with BPH and also build value for our shareholders."

Dennis Turpin, Senior Vice President and Chief Financial Officer of AEterna Zentaris added, "The non-dilutive transactions and the recent partnership with sanofi-aventis have provided the Company with an overall stronger financial position and with the necessary funds to pursue our growth strategy."

CONSOLIDATED RESULTS FOR THE FOURTH QUARTER ENDED DECEMBER 31, 2008

Consolidated revenues were $7.2 million for the quarter ended December 31, 2008, compared to $10.2 million for the same quarter in 2007. The decrease in revenues is primarily due to lower quarter-over-quarter royalties related to our license agreement with Merck Serono. Subsequent to the sale of the Company's rights to royalties on future sales of Cetrotide(R), covered by the Company's license agreement with Merck Serono, to Cowen, which was effective, for royalty determination purposes, on October 1, 2008, our periodic amortization of the gross proceeds received from Cowen, while still recognized as royalty revenues, has been lower than the royalty revenues recognized in the past, as receivable directly from Merck Serono. Additionally, quarter-over-quarter sales and royalties decreased due to the absence of sales of Impavido(R) in the fourth quarter of 2008, while license revenues witnessed a decrease due to the non-recurrence in 2008 of milestone payments received from one of our partners, related to the perifosine Phase 2 trials.

Consolidated selling, general and administrative ("SG&A") expenses were $3.0 million for the quarter ended December 31, 2008, compared to $5.1 million for the same quarter in 2007. The decrease in SG&A expen
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 2014 Research and Markets ... "Spectroscopy Equipment and Accessories - Global ... offering. This report analyzes ... Accessories in US$ Thousands by the following ... Spectrometers, NMR-EPR Spectrometers, Near Infrared (NIR) Spectrometers, ...
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ... today reported results of its Oral Amphotericin B ... reservoirs.  The study, conducted by ImmuneCarta®, the immune ... vitro effectiveness of Oral Amp B in ... in individuals despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... 18, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), a ... and products for advanced microarray diagnostics, today announced it ... 22 at 2:00 pm ET.  During ... a brief review of SQI,s recent commercialization progress and ... industry veteran recently appointed to the Board of Directors ...
(Date:8/18/2014)... Global HIV Infection Drug Market and Pipeline Insight is ... HIV infection and the number of deaths due to AIDS ... across the globe. It has been estimated that the death ... 2013, with the rates for children being even much lower. ... rates has been the improved access to antiretroviral drugs and ...
Breaking Biology Technology:Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... Inc. (Amex:,SGN) has received its second Frost & Sullivan ... 2008, at the Frost & Sullivan Awards Banquet,Signalife was ... American Patient Monitoring. Signalife,s Chief Executive Officer, Dr.,Lowell Harmison, ... present to accept the award., Signalife, Inc. is ...
... result in longer-lasting, safer batteries for ... cars, ... Department of Energy,s,(DOE) Argonne National Laboratory and Toda Kogyo Corp. ... commercial production and,sales of Argonne,s patented composite cathode materials for ...
... March 13 Arpida Ltd,(SWX: ARPN) announced today its ... 2007 highlights, Major pipeline progress:, - Second ... its pre-specified primary endpoint, as did the first, ... iclaprim in,cSSSI initiated, - First patients enrolled in ...
Cached Biology Technology:Signalife Wins Second Frost & Sullivan Technology Award 2Signalife Wins Second Frost & Sullivan Technology Award 3Argonne's Lithium-Ion Battery Technology to be Commercialized by Japan's Toda Kogyo 2Argonne's Lithium-Ion Battery Technology to be Commercialized by Japan's Toda Kogyo 3Arpida Announces Full Year 2007 Financial Results 2Arpida Announces Full Year 2007 Financial Results 3Arpida Announces Full Year 2007 Financial Results 4Arpida Announces Full Year 2007 Financial Results 5Arpida Announces Full Year 2007 Financial Results 6Arpida Announces Full Year 2007 Financial Results 7Arpida Announces Full Year 2007 Financial Results 8Arpida Announces Full Year 2007 Financial Results 9
(Date:8/19/2014)... A team of UTSA researchers has been awarded a ... Technology and Training (NCPTT), an office of the National ... The grant will fund a one-year study of the ... of historic homes in hot, humid climates. , Radiant ... or attics that reflect heat back, thereby reducing the ...
(Date:8/19/2014)... 19, 2014A new ovoid structure discovered in the Nakhla ... a variety of minerals, and shows evidence of undergoing ... of the permafrost and mixing of surface and subsurface ... of analytical studies to determine the origin of this ... this ovoid formed, point to the most likely conclusion, ...
(Date:8/19/2014)... concentrations of African dust transported to South America ... These research findings offer new insight on the ... African dust, including the climate change-induced human health ... African dust emissions in the coming decades., Researchers ... of Marine and Atmospheric Science and colleagues analyzed ...
Breaking Biology News(10 mins):UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3Life on Mars? Implications of a newly discovered mineral-rich structure 2Study of African dust transport to South America reveals air quality impacts 2
... historical water conditions. By synthesizing present-day data with ... trends on a regional basis for periods from which scant ... impede hydrologists, understanding of the current state of waterways and ... was the case for the rivers of the northeastern United ...
... to measure the structure of membrane proteins despite being damaged ... help fast track the development of targeted drugs using emerging ... today depend on the activity of membrane proteins, which are ... our body. A major problem for the design of ...
... crow, a forest crow living on Rota Island in the ... The extinction could happen almost twice as soon as previously ... bird management program that focuses on helping fledgling birds reach ... in psychology. Ha examined survival rates in 97 Mariana ...
Cached Biology News:CCNY-led interdisciplinary team recreates colonial hydrology 2CCNY-led interdisciplinary team recreates colonial hydrology 3Despite damage, membrane protein structure can be seen using new X-ray technology, study reveals 2Without intervention, Mariana crow to become extinct in 75 years 2